HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Combination of a dual 5-lipoxygenase/cyclooxygenase inhibitor with a glucocorticoid results in synergistic topical antiinflammatory activity without inducing skin atrophy.

Abstract
Synthetic glucocorticosteroids are widely used in clinical dermatology in the treatment of a number of inflammatory skin disorders. However, cutaneous side effects such as induction of skin atrophy are among the factors that limit the chronic use of this class of agents. We have found that a combination of a dual 5-lipoxygenase/cyclooxygenase inhibitor (9-phenylnonanohydroxamic acid, BMY 30094) and a glucocorticosteroid (hydrocortisone valerate) has synergistic antiinflammatory activity. Topical application of a 0.2% solution of hydrocortisone valerate alone inhibited phorbol ester-induced mouse skin inflammation by 92%. A 1% solution of BMY 30094 alone or a low dose of hydrocortisone valerate (0.005%) had no significant effect on the inflammatory reaction. A combination of 1% BMY 30094 and 0.005% hydrocortisone valerate inhibited the inflammation by 76%. This latter combination produced no signs of skin atrophy in rats after 28 days of application. In contrast, a 0.1% dose of hydrocortisone valerate produced significant skin atrophy. These findings suggest that it is possible to reduce the skin atrophy potential of glucocorticoids while maintaining the antiinflammatory activity using a novel drug combination.
AuthorsK M Tramposch
JournalInflammation (Inflammation) Vol. 17 Issue 5 Pg. 531-6 (Oct 1993) ISSN: 0360-3997 [Print] United States
PMID8225561 (Publication Type: Comparative Study, Journal Article)
Chemical References
  • Anti-Inflammatory Agents, Non-Steroidal
  • Cyclooxygenase Inhibitors
  • Hydroxamic Acids
  • Lipoxygenase Inhibitors
  • 9-phenylnonanohydroxamic acid
  • hydrocortisone valerate
  • Tetradecanoylphorbol Acetate
  • Hydrocortisone
Topics
  • Administration, Cutaneous
  • Animals
  • Anti-Inflammatory Agents, Non-Steroidal (administration & dosage, pharmacology, therapeutic use)
  • Atrophy (prevention & control)
  • Cyclooxygenase Inhibitors (administration & dosage, pharmacology, therapeutic use)
  • Drug Eruptions (drug therapy, etiology, pathology)
  • Drug Synergism
  • Drug Therapy, Combination
  • Female
  • Hydrocortisone (administration & dosage, analogs & derivatives, pharmacology, therapeutic use)
  • Hydroxamic Acids (pharmacology, therapeutic use)
  • Lipoxygenase Inhibitors (administration & dosage, pharmacology, therapeutic use)
  • Mice
  • Rats
  • Rats, Sprague-Dawley
  • Skin (drug effects, pathology)
  • Tetradecanoylphorbol Acetate (toxicity)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: